Natalizumab for multiple sclerosis: the dilemma of NOVA

Lancet Neurol. 2022 Jul;21(7):579-581. doi: 10.1016/S1474-4422(22)00170-3. Epub 2022 Apr 25.
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Chronic Progressive*
  • Multiple Sclerosis, Relapsing-Remitting*
  • Natalizumab / therapeutic use

Substances

  • Immunologic Factors
  • Natalizumab